

PERSONAL INFORMATION

David Olsen

WORK EXPERIENCE

October 2015–Present

Senior advisor

Statens Legemiddelverk (Norwegian Medicines Agency) (Norway)

Drug safety assessment, PRAC member, provide general advise on medical questions

April 2013–October 2015

Deputy director Nordic Medical affairs and director Nordic medical affairs

Sanofi Pasteur MSD (Norway)

Vaccines, drug safety

September 2010–April 2013

Medical director

Merck Serono (Norway)

Various products

August 2009–September 2010

Nordic medical manager

Gilead Sciences (Sweden)

Various products

August 2006–August 2009

Medical manager and medical director

Merck serono (Denmark)

Various products

November 2004–August 2006

Medical advisor

Boehringer Ingelheim (Denmark)

Various products

January 2000–November 2004

Researcher

Rigshospitalet and Copenhagen Muscle Research center (Denmark)

Physician, Department of Neurology, Rigshospitalet, University of Copenhagen and Basic muscle physiology and pathology research at CMRC

January 1996–January 2000

Physician

University Hospital Copenhagen (various departments) (Denmark)

Internship (physician) at various departments. Research assistant at the MS Research unit, Glostrup Hospital, University of Copenhagen

EDUCATION AND TRAINING

February 1989–January 1996

Medical Doctor (Cand Med)

University of Copenhagen (Denmark)

Medical Doctor

Authorized physician

ADDITIONAL INFORMATION

Expertise	During 2002 - 2004 lieutenant surgeon, Royal Danish Navy.
Publications	<p>Olsen DB, Abraham JH. Neuropsychiatriske forstyrrelser ved insulinom. Ugeskr Laeger 1999;161:1420-21.</p> <p>Olsen DB, Langkilde AR, Schmalbruch H, Vissing J. Diagnostic challenges in combined multiple sclerosis and centronuclear myopathy. Eur J Neurol 2000;7(5):567-571.</p> <p>Olsen DB, Langkilde AR, Rostrup E, Ørngreen MC, Vissing J. Muscle structural changes in mitochondrial myopathy relate to genotype. J Neurol 2003;250:1328-1334.</p> <p>Olsen DB, Ørngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. Neurology 2005;64:1064-1066.</p> <p>Olsen DB, Sacchetti M, Dela F, Ploug T, Saltin B. Glucose clearance is higher in arm than leg muscle in type 2 diabetes. J Physiol 2005;565:555-562.</p> <p>Olsen DB, Gideon P, Jeppesen TD, Vissing J. Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI. J Neurol. 2006;253:1437-41.</p> <p>Olsen DB, Scheede-Bergdahl C, Reving D, Boushel R, Dela F. The effect of rowing on endothelial function and insulin action in healthy controls and in patients with type 2 diabetes. Scand J Med Sci Sports. 2010 Feb 4. [Epub ahead of print]</p> <p>Olsen DB. Vaksinasjon mot helvetesild. Tidsskrift for den Norske Legeforening. 2015;135:834</p> <p>Munch-Andersen T, Olsen DB, Søndergaard H, Daugaard JR, Bysted A, Christensen DL, Saltin B, Helge JW. Metabolic profile in two physically active inuit groups consuming either a western or a traditional diet. Int J Circumpolar Health 2012;71:17342</p> <p>Sacchetti M, Olsen DB, Saltin B, Van Hall G. Heterogeneity in limb fatty acid kinetics in type 2 diabetes. Diabetologia 2005;48:938-945.</p> <p>González-Alonso J, Olsen DB, Saltin B. Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery. Role of circulating ATP. Circ Res 2002;91(11):1046-55</p> <p>Ørngreen MC, Olsen DB, Vissing J. Exercise tolerance in carnitine palmitoyltransferase II deficiency with i.v. and oral glucose. Neurology 2002;59(7):1046-51.</p> <p>Jeppesen TD, Olsen DB, Vissing J. Cycle ergometry is not a sensitive diagnostic test for mitochondrial myopathy. J Neurol 2003;250:293-299.</p> <p>Ørngreen MC, Olsen DB, Vissing J. Aerobic training in patients with myotonic dystrophy type I. Ann Neurol 2005;57:754-757.</p> <p>Jensen TD, Schwartz M, Olsen DB, Vissing J. Oxidative capacity correlates with muscle mutation load in mitochondrial myopathy. Ann Neurol 2003;54:86-92.</p> <p>Sacchetti M, Saltin B, Olsen DB, van Hall G. High triacylglycerol turnover rate in human skeletal muscle. J Physiol 2004;15:883-891.</p> <p>Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Dunø M, Hauerslev S, Vissing J. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain. 2006;129:3402-12</p> <p>Sonne MP, Scheede-Bergdal C, Olsen DB, Højbjerg L, Nielsen NB, Stallknecht B, Helge JW, Dela F. Effects of physical training on endothelial function and limb blood flow in type 2 diabetes. Appl Physiol Nutr Metab 2007;32:936-941.</p> <p>Ørngreen MC, Gideon P, Pedersen HB, Olsen DB, Vissing J. Juvenil asymmetrisk segmental spinal muskel atrofi. Ugeskr Læger 2002;164(35):4073-4075.</p> <p>Sonne MP, Scheede-Bergdahl C, Olsen DB, Højbjerg L, Alibegovic A, Nielsen NB, Stallknecht B, Helge JW, Vaag A, Dela F. Effects of physical training on endothelial function and limb blood flow in type 2 diabetes. APNM 2007 (in press)</p> <p>Wibrand F, Jeppesen TD, Frederiksen AL, Olsen DB, Duno M, Schwartz M, Vissing J. Limited diagnostic value of enzyme analysis in patients with mitochondrial tRNA mutations. Muscle Nerve. 2009 Nov 25. [Epub ahead of print]</p> <p>Caray AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, Hawley JA, Febbraio MA. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 related to fat mass and not insulin responsiveness. Diabetologia 2004;47:1029-1037.</p> <p>Jeppesen TD, Schwartz M, Frederiksen AL, Wibrand F, Olsen DB, Vissing J. Muscle phenotype and</p>

mutation load in 51 persons with the 3243A>G mitochondrial DNA mutation. Arch Neurol 2006;63:1701-6

Klarskov P, Bang LE, Schultz-Larsen P, Petersen HG, Olsen DB, Berg RMG, Abrahamsen H, Wiinberg N. Intensive versus conventional blood pressure monitoring in a general practice population. The blood pressure reduction in Danish general practice trial: a randomized controlled parallel group trial. Fam Pract 2018 Jan 17

Sørensen TL, Trebst C, Kivisäkk P, Klaege KL, Majmudar A, Ravid R, Lasmann H, Olsen DB, Strieter RM, Ransohoff RM, Sellebjerg F. Multiple sclerosis: a study of CXCL10 and CXCR3 colocalisation in the inflamed central nervous system. J Neuroimmunol 2002;127:59-68.

Projects

Memberships

Other Relevant Information